Biohit Oyj’s Chinese Joint Venture to Start Production

- October 24th, 2016

Biohit Oyj’s Chinese joint venture Biohit HealthCare (Hefei) Co. Ltd production facility has passed official test requirements and has been granted a license enabling production and sales of products.

Biohit Oyj’s Chinese joint venture Biohit HealthCare (Hefei) Co. Ltd production facility has passed official test requirements and has been granted a license enabling production and sales of products.
Biohit HealthCare (Hefei) Co. Ltd will start manufacturing of the globally unique GastroPanel®-products developed by Biohit Oyj for the Chinese market, and the first shipments will go to fill orders relating to the ongoing gastric cancer risk screening study which has been expanded to cover over 150 hospitals and expected to be concluded by the end of 2016 on part of the patient screening. The study will continue with statistical data analysis and reporting from various municipalities and hospitals that have taken part in the study. The reporting and analysis phase is expected to be completed during 2017. The results of the analysis will determine if a population based screening program is feasible. In the meantime sales of GastroPanel®-tests has continued in the 14 provinces where price approval has been granted. Biohit Oyj will supply the necessary raw materials and reagents used in production.

CEO Semi Korpela, Biohit Oyj: ‘The approval and official permit process have taken longer than anticipated, but are finally completed. Our joint venture can now produce GastroPanel®-products for the promising Chinese markets cost effectively and in large scale. The GastroPanel® (1,2), which is highly informative and unique in China and elsewhere in the world doesn’t have the serious medical deficiencies as do the helicobacter tests (e.g. 13C urea breath test) still in use (3).’
CEO Liu Feng, Biohit HealthCare (Hefei) Co. Ltd: ‘We have finalised the production facility utilising state of the art technology and process automation for the production, warehousing and logistics of GastroPanel®-products for the Chinese domestic market. The production capacity has been tailored to correspond with the capacity needs of a possible population based screening program.’
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
1. www.biohithealthcare.com/additional-information
2. www.gastropanel.com/decision-makers/screening-model
3. http://www.biohithealthcare.com/limitations-of-helicobacter-pylori-diagnostics
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

Leave a Reply